Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 31

Results For "2023"

1144 News Found

Vijaya Diagnostic Centre posts Q4 FY24 consolidated PAT at Rs. 33.45 Cr
News | May 09, 2024

Vijaya Diagnostic Centre posts Q4 FY24 consolidated PAT at Rs. 33.45 Cr

The company has posted net profit of Rs.118.82 crores for the Financial Year ended March 31, 2024


Aarti Drugs posts Q4 FY24 consolidated PAT at Rs. 47.37 Cr
News | May 09, 2024

Aarti Drugs posts Q4 FY24 consolidated PAT at Rs. 47.37 Cr

The company has posted net profit of Rs.171.42 crores for the Financial Year ended March 31, 2024


AstraZeneca completes equity investment agreement with Cellectis
News | May 08, 2024

AstraZeneca completes equity investment agreement with Cellectis

Cellectis is also eligible to receive an investigational new drug (IND) option fee and development


Suven Life Sciences posts Q4 FY24 consolidated loss at Rs. 26.54 Cr
News | May 07, 2024

Suven Life Sciences posts Q4 FY24 consolidated loss at Rs. 26.54 Cr

The company has posted net loss of Rs. 105.07 crores for the Financial Year ended March 31, 2024


Tatva Chintan Pharma Chem posts Q4 FY24 PAT at Rs. 9.61 Cr
News | May 06, 2024

Tatva Chintan Pharma Chem posts Q4 FY24 PAT at Rs. 9.61 Cr

The company has posted net profit of Rs.30.35 crores for the Financial Year ended March 31, 2024


Astec LifeSciences posts Q4FY24 consolidated loss at Rs. 97.39 lakhs
News | May 04, 2024

Astec LifeSciences posts Q4FY24 consolidated loss at Rs. 97.39 lakhs

The company has reported total income of Rs. 155.79 crores during the period ended March 31, 2024


Dabur India posts Q4 FY24 consolidated PAT at Rs. 349.53 Cr
News | May 04, 2024

Dabur India posts Q4 FY24 consolidated PAT at Rs. 349.53 Cr

The company has reported total income of Rs. 2,943.49 crores during the period ended March 31, 2024


Ajanta Pharma posts Q4 FY24 consolidated PAT at Rs. 202.72 Cr
News | May 04, 2024

Ajanta Pharma posts Q4 FY24 consolidated PAT at Rs. 202.72 Cr

The company has reported total income of Rs. 1,089.58 crores during the period ended March 31, 2024


RPG Life Sciences posts Q4 FY24 PAT at Rs. 13.24 Cr
News | May 03, 2024

RPG Life Sciences posts Q4 FY24 PAT at Rs. 13.24 Cr

The company has posted net profit of Rs.87.66 crores for the Financial Year ended March 31, 2024


Moderna posts Q1 2024 revenues at US$167 million
News | May 03, 2024

Moderna posts Q1 2024 revenues at US$167 million

GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)